Source link : https://www.newshealth.biz/health-news/immune-checkpoint-inhibitors-for-advanced-melanoma-10-year-outcomes-turn-heads/
TOPLINE: The final, 10-year results of the international randomised clinical trial known as CheckMate 067 report that the median overall survival with advanced melanoma is nearly 72 months with the combination of nivolumab + ipilimumab, nearly 37 months with nivolumab monotherapy, and only 20 months with ipilimumab monotherapy. Both agents are immune checkpoint inhibitors, but […]
Author : News Health
Publish date : 2025-01-06 14:00:00
Copyright for syndicated content belongs to the linked Source.